Matthew Call serves as Executive at iTeos Therapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Matthew Call has executed 4 insider transactions totaling $0, demonstrating a balanced approach to their equity position. Their most recent transaction on Aug 29, 2025 involved transacting 161,898 shares valued at $0.
Matthew Call currently holds 137,898 shares of iTeos Therapeutics, Inc. (ITOS), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Matthew Call has been a net neutral trader of ITOS stock. They have purchased $0 and sold $0 worth of shares.
Matthew Call's most recent insider trade was on Aug 29, 2025, when they sold 161,898 shares at $0.00 per share.
Get notified when new Form 4 filings are submitted
| $N/A |
| Discretionary |
| Mar 28, 2023 | ITOS | $118.7K | Option Exercise | 40,226 | $2.95 | Discretionary |
| Jul 30, 2021 | ITOS | $158.3K | Option Exercise | 53,672 | $2.95 | Discretionary |